Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
Impact of continuous glucose monitoring on glycemic control and biochemical cardiovascular risk factors in kidney transplant recipients with type 1 diabetes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Widera Monika, Owczarek Aleksander J, Kolonko Aureliusz, Kamińska Dorota, Świder Robert, Król Robert, Sekta Sylwia, Więcek Andrzej, Ziaja Jacek
Аннотация
AIMS: To compare biochemical risk factors for cardiovascular disease (CVD) in kidney transplant recipients (KTx) with type 1 diabetes (T1D) who used continuous glucose monitoring (CGM) devices or underwent simultaneous kidney and pancreas (SPK) transplantation during long-term follow-up.
MATERIALS AND METHODS: 22 graft recipients with T1D using CGM (KTx CGM) and 22 patients with T1D after SPK were included in the study. Study groups were matched for age and diabetes duration at the time of transplantation, age at the time of the study, sex, body mass index (BMI), total duration of dialysis therapy, dialysis modality, pretransplant CVD, and rates of kidney re-transplantation. Biochemical markers of glycemic control and risk for CVD were assessed over a 9-11 year follow up period.
RESULTS: Fasting plasma glucose (FPG) and HbA1c were higher in the KTx CGM versus SPK group (6.5 [4.9; 7.8] vs 4.7 [4.4; 5.6] mmol/L, p<0.01, and 6.7 [5.9; 7.5] vs 5.2 [5.1; 5.4]%, p<0.001, respectively). Total cholesterol (TC) and high-density lipoprotein (HDL) did not differ between groups. Low-density lipoprotein (LDL) concentrations were lower in the KTx CGM vs the SPK group (2.35 ± 0.66 vs 2.96 ± 1.13 mmol/L, p=0.056). Triglyceride values were higher in the KTx CGM vs SPK group (1.29 ± 0.45 mmol/L vs 1.02 ± 0.39 mmo/L, p<0.05). Serum creatinine was higher (122.7 μmol/L vs 87.2 μmol/L, p< 0.01), and estimated glomerular filtration rates (eGFR) were lower (73.8 ± 25.0 vs 51.3 ± 18.6 ml/min.1.73 m2, p< 0.01) in the KTx CGM vs the SPK group.
CONCLUSIONS: Application of CGM technology in kidney graft recipients with T1D enabled good control of glucose levels and allowed for normalization of a number of biochemical risk factors for CVD. Pancreas transplantation remains the optimal procedure in achieving physiological blood glucose levels in T1D kidney recipients.
MATERIALS AND METHODS: 22 graft recipients with T1D using CGM (KTx CGM) and 22 patients with T1D after SPK were included in the study. Study groups were matched for age and diabetes duration at the time of transplantation, age at the time of the study, sex, body mass index (BMI), total duration of dialysis therapy, dialysis modality, pretransplant CVD, and rates of kidney re-transplantation. Biochemical markers of glycemic control and risk for CVD were assessed over a 9-11 year follow up period.
RESULTS: Fasting plasma glucose (FPG) and HbA1c were higher in the KTx CGM versus SPK group (6.5 [4.9; 7.8] vs 4.7 [4.4; 5.6] mmol/L, p<0.01, and 6.7 [5.9; 7.5] vs 5.2 [5.1; 5.4]%, p<0.001, respectively). Total cholesterol (TC) and high-density lipoprotein (HDL) did not differ between groups. Low-density lipoprotein (LDL) concentrations were lower in the KTx CGM vs the SPK group (2.35 ± 0.66 vs 2.96 ± 1.13 mmol/L, p=0.056). Triglyceride values were higher in the KTx CGM vs SPK group (1.29 ± 0.45 mmol/L vs 1.02 ± 0.39 mmo/L, p<0.05). Serum creatinine was higher (122.7 μmol/L vs 87.2 μmol/L, p< 0.01), and estimated glomerular filtration rates (eGFR) were lower (73.8 ± 25.0 vs 51.3 ± 18.6 ml/min.1.73 m2, p< 0.01) in the KTx CGM vs the SPK group.
CONCLUSIONS: Application of CGM technology in kidney graft recipients with T1D enabled good control of glucose levels and allowed for normalization of a number of biochemical risk factors for CVD. Pancreas transplantation remains the optimal procedure in achieving physiological blood glucose levels in T1D kidney recipients.